Skip to content
EntityQ7939403· pop 9· linked from 142 articles

Also known as A-71100, AO-128, Basen, Glustat

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.

Research

426 papers

via PubMed

Wikidata facts

Mass
267.131802
Show 5 more facts
Commons category
Voglibose
defined daily dose
0.6
chemical formula
C₁₀H₂₁NO₇
canonical SMILES
C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO
isomeric SMILES
C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO
Sources (5)

via Wikidata · CC0

~1 min read

Article

3 sections
Contents
  • Efficacy
  • References
  • Further reading

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was discovered in 1981, and was first launched in Japan in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

Available in 8 languages

via Wikidata sitelinks · CC0

Connections

Categories